BTG receives CE mark certification for radiopaque drug-eluting bead
6 April 2017 | By Niamh Marriott, Junior Editor
BTG has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead...
List view / Grid view
6 April 2017 | By Niamh Marriott, Junior Editor
BTG has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead...
11 June 2015 | By Victoria White
The first patient in Singapore has been treated with TheraSphere radioembolization therapy- a treatment for primary liver cancer and metastatic bowel cancer...